...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients
【24h】

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients

机译：吉西他滨联合紫杉醇或长春瑞滨与单独使用紫杉醇或吉西他滨治疗老年患者或不适合的晚期非小细胞肺癌患者

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to assess whether a combination of gemcitabine (GEM) with either paclitaxel (PTX) or vinorelbine (VNR) could be more effective than GEM or PTX alone in elderly or unfit advanced non-small-cell lung cancer (NSCLC) patients. A total of 264 NSCLC patients aged >70 years with ECOG performance status (PS)2, or younger with PS=2, were randomly treated with: GEM 1200?mg?m?2 on days 1, 8 and 15 every 28 days; PTX 100?mg?m?2 on days 1, 8 and 15 every 28 days; GEM 1000?mg?m?2 plus PTX 80?mg?m?2 (GT) on days 1 and 8 every 21 days; GEM 1000?mg?m?2 plus VNR 25?mg?m?2 (GV) on days 1 and 8 every 21 days. In all arms, an intra-patients dose escalation was applied over the first three courses, provided that no toxicity of WHO grade 2 had previously occurred. At present time, 217 (82%) patients had died. The median (months) and 1-year survival probability were 5.1 and 29% for GEM, 6.4 and 25% for PTX, 9.2 and 44% for GT, and 9.7 and 32% for GV. Multivariate analysis showed that PS1 (hazard ratio (HR)=0.67; 95% CI 0.51–0.90), and doublet treatments (HR=0.76; 95% CI 0.59–0.99) were significantly associated with longer survival. Doublets produced no more toxicity than single agents. GT should be considered a reference regimen for elderly NSCLC patients with PS1.
机译：这项研究的目的是评估吉西他滨（GEM）与紫杉醇（PTX）或长春瑞滨（VNR）的组合是否比单独使用GEM或PTX对老年或不适合的晚期非小细胞肺癌（NSCLC）更有效） 耐心。共有264位年龄> 70岁，ECOG表现状态（PS）2或更年轻的PS = 2的NSCLC患者，每28天随机接受以下治疗：GEM 1200？mg？m？2（每28天一次）;每28天的第1、8和15天PTX 100？mg？m？2;每21天的第1天和第8天提供GEM 1000？mg？m？2和PTX 80？mg？m？2（GT）;每21天的第1天和第8天GEM 1000？mg？m？2加上VNR 25？mg？m？2（GV）。在所有部门中，只要以前没有发生过WHO 2级毒性，就在头三个疗程中对患者进行剂量递增。目前，有217名（82％）患者死亡。 GEM的中位数（月）和1年生存概率分别为5.1和29％，PTX分别为6.4和25％，GT分别为9.2和44％和GV 9.7和32％。多因素分析表明，PS1（危险比（HR）= 0.67; 95％CI 0.51-0.90）和双重治疗（HR = 0.76; 95％CI 0.59-0.99）与更长的生存期显着相关。 Doublets产生的毒性不比单一药剂高。对于老年PS1的NSCLC患者，应考虑将GT作为参考方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号